7 research outputs found
Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial
Biomarkers have proven their ability in the evaluation of cardiopulmonary diseases.We investigated the utility of concentrations
of the biomarker procalcitonin (PCT) alone and with clinical variables for the diagnosis of pneumonia in
patients presenting to emergency departments (EDs) with a chief complaint of shortness of breath.
The BACH trial was a prospective, international, study of 1641 patients presenting to EDs with dyspnoea. Blood
samples were analysed for PCT and other biomarkers. Relevant clinical data were also captured. Patient outcomes
were assessed at 90 days. The diagnosis of pneumonia was made using strictly validated guidelines. A model using
PCT was more accurate [area under the curve (AUC) 72.3%] than any other individual clinical variable for the diagnosis
of pneumonia in all patients, in those with obstructive lung disease, and in those with acute heart failure (AHF).
Combining physician estimates of the probability of pneumonia with PCT values increased the accuracy to .86% for
the diagnosis of pneumonia in all patients. Patients with a diagnosis of AHF and an elevated PCT concentration
(.0.21 ng/mL) had a worse outcome if not treated with antibiotics (P ¼ 0.046), while patients with low PCT
values (,0.05 ng/mL) had a better outcome if they did not receive antibiotic therapy (P ¼ 0.049).
Procalcitonin may aid in the diagnosis of pneumonia, particularly in cases with high diagnostic uncertainty. Importantly,
PCT may aid in the decision to administer antibiotic therapy to patients presenting with AHF in which clinical uncertainty
exists regarding a superimposed bacterial infection
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea : results from the BACH (Biomarkers in Acute Heart Failure) trial
Our purpose was to assess the diagnostic utility of mid-regional pro-atrial natriuretic peptide (MR-proANP) for the diagnosis of acute heart failure (AHF) and the prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with AHF
Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial
Biomarkers have proven their ability in the evaluation of
cardiopulmonary diseases. We investigated the utility of concentrations
of the biomarker procalcitonin (PCT) alone and with clinical variables
for the diagnosis of pneumonia in patients presenting to emergency
departments (EDs) with a chief complaint of shortness of breath.
The BACH trial was a prospective, international, study of 1641 patients
presenting to EDs with dyspnoea. Blood samples were analysed for PCT and
other biomarkers. Relevant clinical data were also captured. Patient
outcomes were assessed at 90 days. The diagnosis of pneumonia was made
using strictly validated guidelines. A model using PCT was more accurate
[area under the curve (AUC) 72.3] than any other individual clinical
variable for the diagnosis of pneumonia in all patients, in those with
obstructive lung disease, and in those with acute heart failure (AHF).
Combining physician estimates of the probability of pneumonia with PCT
values increased the accuracy to 86 for the diagnosis of pneumonia in
all patients. Patients with a diagnosis of AHF and an elevated PCT
concentration (0.21 ng/mL) had a worse outcome if not treated with
antibiotics (P 0.046), while patients with low PCT values (0.05 ng/mL)
had a better outcome if they did not receive antibiotic therapy (P
0.049).
Procalcitonin may aid in the diagnosis of pneumonia, particularly in
cases with high diagnostic uncertainty. Importantly, PCT may aid in the
decision to administer antibiotic therapy to patients presenting with
AHF in which clinical uncertainty exists regarding a superimposed
bacterial infection.
Trial registration: NCT00537628
Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study
Background-In patients with heart failure (HF), increased arginine
vasopressin concentrations are associated with more severe disease,
making arginine vasopressin an attractive target for therapy. However,
AVP is difficult to measure due to its in vitro instability and rapid
clearance. Copeptin, the C-terminal segment of preprovasopressin, is a
stable and reliable surrogate biomarker for serum arginine vasopressin
concentrations.
Methods and Results-The Biomarkers in Acute Heart Failure (BACH) trial
was a 15-center, diagnostic and prognostic study of 1641 patients with
acute dyspnea; 557 patients with acute HF were included in this
analysis. Copeptin and other biomarker measurements were performed by a
core laboratory at the University of Maryland. Patients were followed
for up to 90 days after initial evaluation for the primary end point of
all-cause mortality, HF-related readmissions, and HF-related emergency
department visits. Patients with copeptin concentrations in the highest
quartile had increased 90-day mortality (P<0.001; hazard ratio, 3.85).
Mortality was significantly increased in patients with elevated copeptin
and hyponatremia (P<0.001; hazard ratio, 7.36). Combined end points of
mortality, readmissions, and emergency department visits were
significantly increased in patients with elevated copeptin. There was no
correlation between copeptin and sodium (r=0.047).
Conclusions-This study showed significantly increased 90-day mortality,
readmissions, and emergency department visits in patients with elevated
copeptin, especially in those with hyponatremia. Copeptin was highly
prognostic for 90-day adverse events in patients with acute HF, adding
prognostic value to clinical predictors, ser um sodium, and natriuretic
peptides.
Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique
identifier: NCT00537628.(Circ Heart Fail. 2011;4:613-620.
Increased 90-day mortality in patients with acute heart failure with elevated copeptin : secondary results from the Biomarkers in Acute Heart Failure (BACH) study
In patients with heart failure (HF), increased arginine vasopressin concentrations are associated with more severe disease, making arginine vasopressin an attractive target for therapy. However, AVP is difficult to measure due to its in vitro instability and rapid clearance. Copeptin, the C-terminal segment of preprovasopressin, is a stable and reliable surrogate biomarker for serum arginine vasopressin concentrations